593 related articles for article (PubMed ID: 12224013)
1. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model.
Soo Hoo W; Lundeen KA; Kohrumel JR; Pham NL; Brostoff SW; Bartholomew RM; Carlo DJ
J Immunol; 1999 Jun; 162(12):7343-9. PubMed ID: 10358185
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
[TBL] [Abstract][Full Text] [Related]
4. GM-CSF-surface-modified B16.F10 melanoma cell vaccine.
Gao J; Huang S; Li M; Luo R; Wang X; Takashima A
Vaccine; 2006 Jun; 24(25):5265-8. PubMed ID: 16713660
[TBL] [Abstract][Full Text] [Related]
5. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
7. Recombinant vaccinia virus expressing cytokine GM-CSF as tumor vaccine.
Chatterjee SK; Qin H; Manna S; Tripathi PK
Anticancer Res; 1999; 19(4B):2869-73. PubMed ID: 10652566
[TBL] [Abstract][Full Text] [Related]
8. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
Mach N; Gillessen S; Wilson SB; Sheehan C; Mihm M; Dranoff G
Cancer Res; 2000 Jun; 60(12):3239-46. PubMed ID: 10866317
[TBL] [Abstract][Full Text] [Related]
9. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4.
Wakimoto H; Abe J; Tsunoda R; Aoyagi M; Hirakawa K; Hamada H
Cancer Res; 1996 Apr; 56(8):1828-33. PubMed ID: 8620500
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
11. Genetically engineered tumor cell vaccine in a head and neck cancer model.
Couch M; Saunders JK; O'Malley BW; Pardoll D; Jaffee E
Laryngoscope; 2003 Mar; 113(3):552-6. PubMed ID: 12616213
[TBL] [Abstract][Full Text] [Related]
12. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF.
Shi FS; Weber S; Gan J; Rakhmilevich AL; Mahvi DM
Cancer Gene Ther; 1999; 6(1):81-8. PubMed ID: 10078967
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells.
Armstrong CA; Botella R; Galloway TH; Murray N; Kramp JM; Song IS; Ansel JC
Cancer Res; 1996 May; 56(9):2191-8. PubMed ID: 8616871
[TBL] [Abstract][Full Text] [Related]
16. Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy.
Shrayer DP; Bogaars H; Hearing VJ; Wanebo HJ
J Exp Ther Oncol; 1996 Mar; 1(2):126-33. PubMed ID: 9414396
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice.
Ling X; Wang Y; Dietrich MF; Andreeff M; Arlinghaus RB
Oncogene; 2006 Jul; 25(32):4483-90. PubMed ID: 16547503
[TBL] [Abstract][Full Text] [Related]
18. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
19. [The anti-tumor activity of GM-CSF-modified lung cancer cell vaccine and its synergism in combination with chemotherapy].
Jiang HJ; Ren XB; Li H; Yu JP; Wei F; Ma MQ
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):808-12. PubMed ID: 18396635
[TBL] [Abstract][Full Text] [Related]
20. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]